Freenome (NASDAQ:FRNM) Hits New 52-Week High – Should You Buy?

Freenome (NASDAQ:FRNM)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $15.25 and last traded at $15.1950, with a volume of 79090 shares changing hands. The stock had previously closed at $14.79.

Analyst Ratings Changes

Several equities analysts have recently issued reports on FRNM shares. Leerink Partners initiated coverage on Freenome in a research report on Friday, August 14th. They issued an “outperform” rating and a $18.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 price objective on the stock. TD Cowen assumed coverage on shares of Freenome in a research note on Tuesday, August 18th. They set a “buy” rating and a $17.00 price objective for the company. BTIG Research started coverage on Freenome in a research note on Monday, August 17th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Guggenheim started coverage on shares of Freenome in a research report on Thursday, August 20th. They set a “buy” rating and a $21.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Freenome presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Freenome Stock Performance

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.